NASDAQ: VRTX · Biotechnology

Vertex Pharmaceuticals (VRTX) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Vertex Pharmaceuticals (VRTX) at $508.20 a share. The stock last closed at $537.79, which puts the model's fair value 5.5% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Vertex Pharmaceuticals Incorporated.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$508.20midpoint of 2,000 simulations
Last close$537.79NASDAQ: VRTX
Gap to fair value-5.5%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $513.83 to $508.20 (-1.1%). The stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move.

What the model makes of itThe price of $537.79 is 5.5% above it: Fairly valued, on a medium evidence grade.

What's nextNext report on 11 Feb 2027. Options prices imply a move of about 10% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give VRTX?

The calibrated range for VRTX over 63 trading days is $478.57 to $607.90. It sits around the last close, and its width comes from the volatility that VRTX's own options imply (35% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $315.42 to $797.98. In 46% of the simulations the fair value came out above the price the model ran on.

$179.61$1,514.77
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $508.20. Dashed line: the last close, $537.79.

Faircurve Insights · 14 Nov 2026

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm focused on discovering, advancing and marketing innovative treatments, particularly for cystic fibrosis (CF). Faircurve's model valued the company on 14 Nov 2026.

The model's fair value is $508.20 a share, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $513.83, a move of -1.1%. In the model's words, the stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move. The calibrated range over 63 trading days is $478.57 to $607.90. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium, which looks at input completeness, comparable companies and the spread of outcomes. It does not say whether the fair value is right.

Vertex scores 55 out of 100 on the model's quality measure, a composite of six factors scored against comparable companies. Three factors stand out. Stability scores 1, with five-year EBITDA margin downside volatility of 14.1 points against a peer median of 3.8 points. Earnings quality scores 32, with FCF to net income of 0.81x against a peer median of 1.08x. Balance sheet scores 81, with net debt to EBITDA of 0.30x against a peer median of 1.31x. The model compares the company with Regeneron Pharmaceuticals, Moderna, Roivant Sciences, United Therapeutics and Incyte.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does VRTX report earnings, and how has the stock reacted?

Vertex Pharmaceuticals's next earnings report is scheduled for 11 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 4.4% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. VRTX's 30 day implied volatility works out to about 10.2% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across VRTX's last 8 reports, ignoring direction, was 4.0%.

0%5%10%15%20%4.5%3.0%10 Feb '254.8%10.2%5 May '256.5%18.9%4 Aug '256.8%0.9%3 Nov '257.7%6.6%12 Feb '266.1%0.1%4 May '265.9%0.3%3 Aug '267.3%5.0%2 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in VRTX

0%5%10%15%2 Nov '26 report3 Aug '26 report4 May '26 report12 Feb '26 report10% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 8% on 14 Nov 2025, reached 13% on 6 Mar 2026 and reads 10% on 16 Nov 2026. The marks are report dates.

How does VRTX score on business quality?

Vertex Pharmaceuticals's overall quality score is 55 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.6616.4%ROIC13.5%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).320.81xFCF / net income1.08x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.679.6%Revenue growth, trailing1.9%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.680.9%Net buybacks / market value0.5%
Balance sheetNet debt to EBITDA and interest coverage.810.30xNet debt / EBITDA1.31x
StabilityDownside volatility of the EBITDA margin over the last five years.114.1 ptsEBITDA margin downside volatility, 5y3.8 pts

How does VRTX compare with similar companies?

The companies in biotechnology closest to Vertex Pharmaceuticals in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
REGN Regeneron Pharmaceuticals, Inc.$952.40$997.74+4.8%Fairly valued
MRNA Moderna, Inc.$215.27$185.21-14.0%Fairly valued
ROIV Roivant Sciences Ltd.$38.61$26.96-30.2%Overvalued
INSM Insmed Incorporated$122.88$113.05-8.0%Low evidence grade
UTHR United Therapeutics Corporation$587.88$601.98+2.4%Fairly valued
INCY Incyte Corporation$120.27$136.90+13.8%Fairly valued
ALNY Alnylam Pharmaceuticals, Inc.$159.73$165.54+3.6%Low evidence grade
EXEL Exelixis, Inc.$67.10$68.00+1.3%Low evidence grade

What the comparable companies' multiples alone would give for VRTX, the peer-implied price, is $382.22 a share on this run. The fair value weighs that against the company's own multiple.

All biotechnology stocks ranked by gap to fair value

Vertex Pharmaceuticals at a glance

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF).

Market value
$136.6B
Sector
Healthcare
Industry
Biotechnology
Revenue expected, next twelve months
$14.5B
Consensus revenue growth, next fiscal year
+9.8%
Analysts with estimates
17
Beta to the US market
0.33
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. VRTX was not among them.

How the fair value is worked out: the model prices Vertex Pharmaceuticals on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for VRTX was $513.83. As of 14 Nov 2026 it is $508.20, a change of -1.1%. The stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Vertex Pharmaceuticals's valuation

Is Vertex Pharmaceuticals stock undervalued or overvalued?

On Faircurve's model, VRTX reads as Fairly valued as of 14 Nov 2026. The model's fair value is $508.20 a share against a last close of $537.79, a gap of -5.5%.

What is VRTX's fair value?

$508.20 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $315.42 to $797.98.

What price range does the model give VRTX?

$478.57 to $607.90 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Vertex Pharmaceuticals report earnings next?

The next report is scheduled for 11 Feb 2027. Companies can move their dates.

How much has VRTX moved on past earnings reports?

Across its last 8 reports the median two session move was 4.0%, ignoring direction. The largest was -18.9% around the report of 4 Aug 2025.

How confident is the model in this valuation?

The model's evidence grade for VRTX is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on VRTX

The model holds no idea open on VRTX today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on VRTX with their outcomes. A free account is enough.

Keep reading